PMID- 37475973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230722
IS  - 2233-4718 (Electronic)
IS  - 2093-940X (Print)
IS  - 2233-4718 (Linking)
VI  - 29
IP  - 3
DP  - 2022 Jul 1
TI  - Clinical Implications of Shared Epitope and Anti-citrullinated Peptide Antibody 
      in Patients With Rheumatoid Arthritis.
PG  - 171-180
LID - 10.4078/jrd.2022.29.3.171 [doi]
AB  - OBJECTIVE: The shared epitope (SE) and anti-citrullinated peptide antibody (ACPA) 
      are involved in the pathogenesis of rheumatoid arthritis (RA). This study 
      evaluated the clinical implications of SE and ACPA in terms of disease 
      manifestation and response to biologic disease modifying anti-rheumatic drugs 
      (DMARDs). METHODS: Patients with identified human leukocyte antigen (HLA)-DRB1 
      alleles were included to compare the clinical characteristics and drug survival 
      rate of tumor necrosis factor (TNF) inhibitors or abatacept based on the presence 
      of SE and ACPA. RESULTS: Of the 533 patients with identified HLA-DRB1 alleles, 
      329 patients (61.7%) with SE alleles showed higher disease activity and erosive 
      changes compared to patients without SE alleles. SE-positive patients were more 
      likely to start biologic (b-) or targeted synthetic DMARDs (tsDMARDs) within the 
      first 5 years (p=0.020). The presence of SE, smoking, dyslipidemia, and higher 
      erythrocyte sedimentation rate were independently associated with the initiation 
      of b- or tsDMARDs (p=0.016, 0.028, 0.031, and 0.001, respectively). The presence 
      of SE and ACPA did not affect the drug survival rate of TNF inhibitors, whereas 
      the abatacept retention rate was higher in ACPA-positive patients (p=0.024). 
      CONCLUSION: The presence of SE affected disease characteristics and prognosis in 
      Korean patients with RA without a significant impact on drug survival rate of TNF 
      inhibitors and abatacept. ACPA positivity was associated with abatacept drug 
      retention, suggesting that abatacept may be helpful in ACPA-positive patients 
      than in ACPA-negative patients.
CI  - Copyright (c) 2022 by The Korean College of Rheumatology. All rights reserved.
FAU - Jung, Seung Min
AU  - Jung SM
AUID- ORCID: 0000-0003-3465-2181
AD  - Division of Rheumatology, Department of Internal Medicine, St. Vincent's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Park, Yune-Jung
AU  - Park YJ
AUID- ORCID: 0000-0002-7346-0820
AD  - Division of Rheumatology, Department of Internal Medicine, St. Vincent's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Park, Kyung-Su
AU  - Park KS
AUID- ORCID: 0000-0003-0020-003X
AD  - Division of Rheumatology, Department of Internal Medicine, St. Vincent's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Kim, Ki-Jo
AU  - Kim KJ
AUID- ORCID: 0000-0002-3598-2396
AD  - Division of Rheumatology, Department of Internal Medicine, St. Vincent's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Rheum Dis
JT  - Journal of rheumatic diseases
JID - 101571816
PMC - PMC10324929
OTO - NOTNLM
OT  - Abatacept
OT  - Antibodies
OT  - Epitopes
OT  - Rheumatoid arthritis
COIS- CONFLICT OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2023/07/21 06:42
MHDA- 2023/07/21 06:43
PMCR- 2022/07/01
CRDT- 2023/07/21 03:58
PHST- 2022/03/18 00:00 [received]
PHST- 2022/04/26 00:00 [revised]
PHST- 2022/05/13 00:00 [accepted]
PHST- 2023/07/21 06:43 [medline]
PHST- 2023/07/21 06:42 [pubmed]
PHST- 2023/07/21 03:58 [entrez]
PHST- 2022/07/01 00:00 [pmc-release]
AID - jrd-29-3-171 [pii]
AID - 10.4078/jrd.2022.29.3.171 [doi]
PST - ppublish
SO  - J Rheum Dis. 2022 Jul 1;29(3):171-180. doi: 10.4078/jrd.2022.29.3.171.